We were thrilled to host another Lhasa Limited Symposium in Seoul, South Korea, alongside BITEK CHEMS.
On 15th October 2024, we brought together professionals from industry and regulatory bodies to address critical topics in chemical safety, with a particular focus on the ongoing challenges of nitrosamine risk assessment. The event offered valuable insights from experts on ICH M7 assessment, nitrosamine risk assessment, the application of innovative in silico tools, and the latest regulatory guidance.
External guest speakers included:
- Brian Seo, BITEK CHEMS
- Professor Yong–Moon Lee, Chungbuk National University
- Dr Mike Urquhart, Scientific Director, Drug Substance Development, GSK
- Dr Andrew Teasdale, Senior Principal Scientist, AstraZeneca, and Chair of AstraZeneca’s Impurity Advisory Board
- Dr Raphael Nudelman, Nudelman ChemTox Consulting
- Luccas Sanches, Researcher, Spektra Consultoria
Topics at the Symposium included:
- Accelerating ICH M7 Assessment
- ICH M7: Control of Impurities
- Nitrosamine Risk Assessment